Norgine’s PEDMARQSI Approved in Australia for Child Cancer Patients
Norgine has achieved a significant regulatory milestone with the Australian Therapeutic Goods Administration approving PEDMARQSI for protecting children undergoing cisplatin chemotherapy from permanent hearing damage. This approval addresses a critical gap in pediatric oncology care where ototoxicity has long posed a serious threat to young cancer survivors.
Norgine’s PEDMARQSI Approved in Australia for Child Cancer Patients Read More »









